Chat with Filing

Ask questions about this document

Please log in or register to use the chat feature. Please register first.

MANG - Expansion of the Executive Board of HAEMATO AG: Strengthening operational excellence

Company: Haemato AG Date: 2022-03-28 Language: English Register to download

Loading document preview...

Document Preview Not Available

The file type (.html) cannot be displayed directly here.

Open Original File

Error loading document preview. Please try the 'Open Original File' link.

You're One Click Away From The Full Filing

Instantly access this document—and 2.8M more—for free. Select your preferred method:

Continue with Google Continue with Microsoft Continue with Facebook Continue with Amazon

 News Details

Corporate | 28 March 2022 18:41

#   

Expansion of the Executive Board of HAEMATO AG: Strengthening operational excellence

DGAP-News: HAEMATO AG / Key word(s): Personnel  

28.03.2022 / 18:41  

The issuer is solely responsible for the content of this announcement.  

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**Expansion of the Executive Board of HAEMATO AG: Strengthening operational excellence**

Schönefeld, 28.03.2022 – In its meeting today, the Supervisory Board of HAEMATO AG appointed Mr. Attila Strauss to the Executive Board of HAEMATO AG with effect from 01.04.2022.

Mr. Attila Strauss has already been working as Chief Operating Officer at HAEMATO PHARM GmbH since 01.05.2021 and has also been Managing Director of the company since 01.10.2021.

Mr. Strauss is 37 years old and studied business informatics. Before joining the HAEMATO Group, Mr. Strauss was responsible for audit and efficiency improvement projects in various multinational companies.

Mr. Patrick Brenske, former sole member of the Executive Board of HAEMATO AG: “In the past months, Mr. Strauss has proven his ability to implement cost reductions and efficiency increases in operational processes. I am pleased about the reinforcement and the further successful cooperation with Mr. Strauss.”

**About HAEMATO:**

HAEMATO AG was founded in 1993 and is a pharmaceutical company focusing on the trade of high-priced specialty pharmaceuticals (with a therapeutic focus on oncology, HIV, rheumatology and other chronic diseases) as well as the development and distribution of medical products and private brands, particularly in the area of “Lifestyle & Aesthetics”. HAEMATO AG is listed on the Basic Board (Open Market) of the Frankfurt Stock Exchange. For further information, please visit www.haemato.de.

  

  

  

Contact:  

HAEMATO AG, Investor Relations  

Telefon: +49 (0)30 897 30 86 70  

ir@haemato.ag

  

- - -

28.03.2022 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.  

The issuer is solely responsible for the content of this announcement.  

  

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.  

Archive at www.dgap.de  

- - -

|     |     |
| --- | --- |
| Language: | English |
| Company: | HAEMATO AG |
|     | Lilienthalstraße 5c |
|     | 12529 Schönefeld |
|     | Germany |
| Phone: | +49 (0)30 897 30 86 70 |
| Fax: | +49 (0)30 897 30 86 79 |
| E-mail: | ir@haemato.ag |
| Internet: | www.haemato.ag |
| ISIN: | DE000A289VV1 |
| WKN: | A289VV |
| Listed: | Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Basic Board), Hamburg, Stuttgart, Tradegate Exchange |
| EQS News ID: | 1313725 |

  

|     |     |
| --- | --- |
|     |     |
| End of News | DGAP News Service |

![show this](https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1313725&application_name=news&site_id=news_data)